The development of LDCT screening for lung cancer was a significant advance; there are patient populations that were not included in the original studies. The current criteria for LDCT is based on age and history of tobacco use, and more accurate risk models have been developed, and recent studies have investigated patient populations defined by factors other than age and history of tobacco use. Blood based tests may compliment LDCT, and a number of different tests are being evaluated in clinical trials.
The current risk models have been published but not adopted, and recent studies have revealed increased risk in patient populations outside the standard criteria.
Attendees need to determine when and how the latest science will affect their day-to-day practice, and thus be able to narrow competency gaps across the various stages of NSCLC most commonly treated with immunotherapy. Awareness of recent findings will improve understanding of the risk/benefit ratio of LDCT. Participation in LDCT is low among eligible patients (<10%), and additional information may improve participation in LDCT and clinicians will be better able to discuss the risks and benefits of LDCT with patients.
Early detection for lung cancer involves multiple specialties including primary care, pulmonary medicine, radiologists and thoracic surgeons. Consequently, many centers have developed multidisciplinary LDCT screening programs. Despite the established mortality benefit of LDCT screening patient participation remains low. Some patient populations are disproportionately excluded from the current eligibility criteria. Blood based testing has the potential to improve the performance of LDCT and/or identify patient populations in need of screening or at higher risk of developing lung cancer. This session will review risk models, ongoing studies in patient populations outside the standard criteria, and emerging role of blood based tests in lung cancer screening.
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.
Upon completion of this activity, participants should be able to do the following:
- Better understand of risk models to predict risk of lung cancer and benefit from LDCT.
- Describe the role of LDCT in patient populations outside the standard criteria based on age and tobacco use.
- Understand of the role of blood based tests in screening or to complement LDCT.
- Thomas Stinchcombe, MD
- Julie Wu, MD, PhD
- Elaine Shum, MD
- Aadel Chaudhuri, MD
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.